Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Jacobsen

Showing results (21-30 of 65) with videos related to

Pageof 7
Sort By:
The Oncologist|August 10, 2022
Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin LymphomaDeepa Jagadeesh, Steve Horwitz, Nancy L Bartlett, et al.
Leukemia & Lymphoma|March 30, 2026
Allogeneic transplant outcomes in T-cell prolymphocytic leukemia: a single-center retrospective studyMwanasha Merrill, Haesook T Kim, Amar H Kelkar, et al.
Leukemia & Lymphoma|November 25, 2020
A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assayMatthew L Chase, Reid Merryman, David C Fisher, et al.
British Journal of Haematology|August 30, 2008
Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disordersJennifer R Brown, Donna Neuberg, Kimberly Phillips, et al.
Blood Advances|April 19, 2022
Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosisMahasweta Gooptu, Haesook T Kim, Eric Jacobsen, et al.
Leukemia & Lymphoma|July 12, 2014
Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphomaEric Jacobsen, Olga Pozdnyakova, Robert Redd, et al.
Haematologica|November 13, 2012
Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphomaJeffrey A Barnes, Eric Jacobsen, Yang Feng, et al.
Blood Cancer Journal|April 17, 2025
Long-term outcomes and clinical phenotypes associated with best response to low dose alemtuzumab in cutaneous T-cell lymphomaCecilia Larocca, Ai-Tram N Bui, John T O'Malley, et al.
Clinical and Translational Science|October 28, 2025
Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug-Drug Interaction Study in Patients With Non-Hodgkin LymphomaMasaya Tachibana, Steven Horwitz, Eric Jacobsen, et al.
Blood Advances|September 2, 2022
Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphomaJeremy S Abramson, Elizabeth Bengston, Robert Redd, et al.
Pageof 7

Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
The Oncologist|August 10, 2022
Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin LymphomaDeepa Jagadeesh, Steve Horwitz, Nancy L Bartlett, et al.
Leukemia & Lymphoma|March 30, 2026
Allogeneic transplant outcomes in T-cell prolymphocytic leukemia: a single-center retrospective studyMwanasha Merrill, Haesook T Kim, Amar H Kelkar, et al.
Leukemia & Lymphoma|November 25, 2020
A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assayMatthew L Chase, Reid Merryman, David C Fisher, et al.
British Journal of Haematology|August 30, 2008
Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disordersJennifer R Brown, Donna Neuberg, Kimberly Phillips, et al.
Blood Advances|April 19, 2022
Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosisMahasweta Gooptu, Haesook T Kim, Eric Jacobsen, et al.
Leukemia & Lymphoma|July 12, 2014
Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphomaEric Jacobsen, Olga Pozdnyakova, Robert Redd, et al.
Haematologica|November 13, 2012
Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphomaJeffrey A Barnes, Eric Jacobsen, Yang Feng, et al.
Blood Cancer Journal|April 17, 2025
Long-term outcomes and clinical phenotypes associated with best response to low dose alemtuzumab in cutaneous T-cell lymphomaCecilia Larocca, Ai-Tram N Bui, John T O'Malley, et al.
Clinical and Translational Science|October 28, 2025
Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug-Drug Interaction Study in Patients With Non-Hodgkin LymphomaMasaya Tachibana, Steven Horwitz, Eric Jacobsen, et al.
Blood Advances|September 2, 2022
Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphomaJeremy S Abramson, Elizabeth Bengston, Robert Redd, et al.
Pageof 7